MedTrace Logo

CoronaWatch - Early Detection of Cardiovascular Risks in COVID-19 Via SmartWatch

NCT04376853 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2022-05-26

No results posted yet for this study

Summary

In December 2019, a new viral disease called COVID-19 emerged. It is caused by the new corona virus SARS-CoV-2. It was initially described in the chinese city of Wuhan. In the following months, the disease developed into a pandemic, which is currently an immense international challenge.

So far, there is little scientific evidence on risk stratification, especially on the prognostic value of biomarkers (laboratory-chemical, clinical and digital) with regard to clinical deterioration of patients with COVID-19. Further scientific studies are needed to establish optimal risk stratification and early detection of clinical deterioration.

In this study, the investigators aim to observe patients with COVID-19 via SmartWatches on top of their clinical routine. The investigators aim to determine, whether the addition of SmartWatches enhances risk stratification, early detection of complications and prognostics in patients with COVID-19, who have cardiovascular diseases or receive medication with arrhythmogenic risk.

Conditions

Interventions

DEVICE

Apple Watch Series 5

Digital monitoring via Apple Watch

Sponsors & Collaborators

  • The German Heart Foundation

    collaborator OTHER

  • Klaus Tschira Stiftung, Germany

    collaborator UNKNOWN

  • Freunde und Förderer der Kardiologie Heidelberg; Germany

    collaborator UNKNOWN

  • University Hospital Heidelberg

    lead OTHER

Principal Investigators

  • Benjamin Meder, Prof. Dr. · University Hospital Heidelberg

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-15
Primary Completion
2022-05-20
Completion
2022-05-20

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04376853 on ClinicalTrials.gov